Last €80.25 EUR
Change Today +0.58 / 0.72%
Volume 0.0
6COP On Other Exchanges
New York
As of 12:11 PM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

covidien plc (6COP) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/27/14 - €80.25
52 Week Low
12/16/13 - €46.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COVIDIEN PLC (6COP)

covidien plc (6COP) Related Businessweek News

View More BusinessWeek News

covidien plc (6COP) Details

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company operates through Medical Devices and U.S. Medical Supplies segments. It sells advanced surgical solutions comprising stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and ablation products, and interventional lung and gastrointestinal solutions, as well as general surgical solutions, including surgical instruments, sutures, and electrosurgery products; and peripheral vascular therapies, such as compression, dialysis, venous insufficiency, peripheral stents, directional artherectomy, and other products, as well as neurovascular therapies comprising coils, neurovascular stents, flow diversion products, and access and delivery products to support procedures. The company also offers patient monitoring products, such as sensors, monitors, and temperature management products; airway and ventilation products, including airway, ventilator, and inhalation therapy products, as well as breathing systems; and nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products. In addition, it sells patient care products, such as operating room supply products and electrodes; original equipment manufacturer products; and SharpSafety products comprising needles, syringes, and sharps disposal products. The company’s products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. It markets its products through direct sales force and third-party distributors. Covidien plc is based in Dublin, Ireland.

39,500 Employees
Last Reported Date: 11/24/14

covidien plc (6COP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $783.5K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and Group President
Total Annual Compensation: $556.6K
Senior Vice President and General Counsel
Total Annual Compensation: $580.9K
Compensation as of Fiscal Year 2013.

covidien plc (6COP) Key Developments

Covidien's Fortrex(TM) PTA Balloon Receives FDA 510(k) Clearance

Covidien plc announced U.S. Food and Drug Administration 510(k) clearance for its Fortrex(TM) over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex(TM) 0.035" OTW PTA balloon catheter --the next-generation high pressure solution to maintain arteriovenous (AV) access--is also intended for use in the peripheral vascular system. A common procedure is to maintain AV access in patients receiving hemodialysis for chronic kidney disease or end stage renal failure. The Fortrex(TM) PTA balloon provides physicians with a high pressure solution to crack the short, fibrous lesions that can block AV access. Furthermore, its unique engineering provides clinicians with: Optimized balloon delivery: Fortrex(TM) PTA balloon's low tip entry profile and robust, flexible shaft design combine to enable tight tracking to the wire and successful navigation in tortuous vessels. Predictable and targeted treatment: The balloon material and design permit shape retention at rated burst pressure, ensuring focused pressure on the lesion for controlled, targeted and predictable treatment. Procedural efficiency: The combination of balloon material and wall thickness enables reliable balloon rewrap and reinsertion along with a top tier deflation time, all of which contribute to the efficiency of the procedure.

Covidien Announces Favorable Results from Iliac Stenosis Study

Covidien plc has announced favorable nine-month results from the DURABILITY Iliac study, conducted with its EverFlex stent, indicated for the treatment of iliac stenosis. The nine-month results confirm the safety and effectiveness of the EverFlex and Protege GPS self-expanding stent systems for the treatment of lesions of the common and external iliac arteries. The EverFlex and Protege GPS self-expanding stent systems demonstrated strong patency rates even in difficult to treat calcified lesions in patients with iliac disease. This data, along with the robust EverFlex stent data in the superficial femoral artery, speaks to the clinical versatility of the system.

Covidien plc Announces Six-Month Results of the VeClose Pivotal Study

Covidien plc announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system in patients with chronic venous insufficiency (CVI) having symptomatic reflux in the great saphenous vein. The results were presented at American College of Phlebology Annual Congress (ACP 2014) in Phoenix, Ariz. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal(TM) system to that of the ClosureFast(TM) endovenous radiofrequency ablation catheter. Covidien's ClosureFast(TM) catheter is an endovenous radiofrequency (RF) ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal(TM) system, which is not approved and currently limited to investigational use in the United States, is a minimally invasive procedure that uses a specially formulated medical adhesive to close the great saphenous vein. Additionally, the VenaSeal(TM) system eliminates the need for surgery, thermal ablation and tumescent anesthesia. Two hundred and forty-two patients were enrolled in the trial, of which 108 were randomized to receive treatment with the VenaSeal(TM) system and 114 with the ClosureFast(TM) catheter. Twenty patients were enrolled as roll-in/training cases and treated with the VenaSeal(TM) system. The results showed outcomes for the VenaSeal(TM) system comparable with the excellent closure rates associated with the ClosureFast(TM) catheter and demonstrated non-inferiority of the VenaSeal(TM) system: At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal(TM) system compared to 95.6% of patients treated with the ClosureFast(TM) catheter; The closure rate at six months was 98.9% and 94.3% for the VenaSeal(TM) system and the ClosureFast(TM) catheter, respectively; Additionally, there were no significant differences in patient reported pain during or at three days post procedure between the groups. Additionally, in October 2014, the Journal of Vascular Surgery published results from the European Sapheon(TM) Closure System Observational ProspectivE (eSCOPE) study, which demonstrated significant improvement in venous symptoms with a cumulative 12 month closure rate of 92.9%. The results also demonstrated the VenaSeal(TM) system improves patients' quality of life.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6COP:GR €80.25 EUR +0.58

6COP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $72.40 USD -0.04
Becton Dickinson and Co $141.26 USD +6.53
Fresenius Medical Care AG & Co KGaA €59.74 EUR +0.32
Stryker Corp $92.37 USD +0.47
Tyco International Plc $42.85 USD -0.53
View Industry Companies

Industry Analysis


Industry Average

Valuation 6COP Industry Range
Price/Earnings 27.6x
Price/Sales 4.3x
Price/Book 4.5x
Price/Cash Flow 27.4x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at